MedTrace Logo

Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

NCT02666209 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2017-08-28

No results posted yet for this study

Summary

Participant that has been diagnosed with Relapsed/ Refractory Multiple Myeloma and are currently participating in a clinical trial which is closing. This research study is studying Ulocuplumab as a possible treatment. It's an expanded access from NCT01359657

Conditions

Interventions

DRUG

Ulocuplumab

CXCR4 inhibitor given weekly on a 28 day cycle intravenously

DRUG

Lenalidomide

immunomodulatory agent given days 1-21 of a 28 day cycle orally in subjects not receiving bortezomib

DRUG

Bortezomib

proteasome inhibitor given at physician discretion in subjects not receiving lenalidomide

DRUG

Dexamethasone

steroid given at physician discretion on a 28 day cycles

Sponsors & Collaborators

Principal Investigators

  • Irene M Ghobrial, MD · Dana-Farber Cancer Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02666209 on ClinicalTrials.gov